Shyam Sampat

Hello, sir. Good evening. I just wanted to understand firstly on the Vizag land that you mentioned that we have taken pos session. Keeping that in mind, will our CAPEX deployment schedule look like for the next FY27 given the current volatility that we have with pharma intermediates, how will you be facing this CAPEX?

Alright, understood. Sir, the next question that I have is regarding contrast media. In the presentation, you mentioned that the top four players hold 75% of the share. So, will our strategy be looking like gaining more wallet share now with those players?

Alright, sir, understood. Sir, regarding the presentation on page #6, we had a line mentioning that EBITDA was impacted by engagement of a foreign consultant. I just wanted to understand the nature of this engagement -- is it one-off or recurring?